AM-Pharma appoints new chief executive

pharmafile | September 13, 2011 | Appointment | Manufacturing and Production, Research and Development |  appointment, manufacturing and production, research and development 

Dutch biopharmaceutical company AM-Pharma has appointed Erik van den Berg as its new chief executive.

He was previously VP business development at the company, which focuses on the preclinical and clinical development of alkaline phosphatase (AP) for the treatment of severe inflammatory diseases.

Erik takes over from Bart Wuurman who AM-Pharma said has left after four years at the helm to take on a new challenge in his career.

AM-Pharma’s chairman Eric Claassen said: “Bart has made a distinctive contribution to the development of AM-Pharma and I would like to thank him for his efforts in turning AM-Pharma into a focused organisation, and for his role in preparing a new round of upcoming financing for the company.”